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ABSTRACT
Donepezil and Galanin Interactions in an Animal Model of Alzheimer’s Disease
by
Jonathan Jacob Sabbagh
Dr. Jefferson Kinney, Examination Committee Chair
Assistant Professor of Psychology
University of Nevada, Las Vegas

Alzheimer’s disease (AD) is a neurodegenerative disorder marked by a
progressive loss of cognitive function. One of the neurobiological hallmarks of AD is a
progressive loss of cholinergic neurons and a decrease in the amount of acetylcholine in
the brain. Pharmacological therapies have targeted the cholinergic system, specifically
first-line, palliative treatment using acetylcholinesterase (AChE) inhibitors, such as
donepezil. Donepezil has been shown to increase cholinergic tone and ameliorate some of
the cognitive deficits in AD patients. Galanin, a neuropeptide that inhibits the evoked
release of several neurotransmitters including acetylcholine as well as modulates seveal
intracellular cascades, is overexpressed in AD resulting in an as yet unidentified
modulation of neurobiological function. Galanin also impairs learning and memory when
administered centrally to rodents, suggesting it may contribute to the cognitive
impairments observed in AD. While the mechanism by which galanin impairs learning
has yet to be determined, studies suggest it is through cholinergic mechanisms. We
investigated the ability of donepezil to rescue learning and memory deficits induced by
galanin administration, and by extension isolated whether the learning impairments
produced by galanin were ameliorated by increasing cholinergic tone. We also
investigated the effects of donepezil and galanin in an animal model of AD, i.e. their
iii

effects on learning and memory following a slight lesion of cholinergic neurons
analogous to the cholinergic loss seen in AD. This study provides vital information about
the relationship between galanin-induced deficits and acetylcholine, and helps to clarify
the roles of donepezil and galanin in AD.
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CHAPTER 1
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a
progressive loss of memory and a decline in cognitive function (Heese & Akatsu, 2006).
It is the most common cause of age-related dementia accounting for 50-60% of agerelated cases. The average age of onset for AD is 65 years, while most cases occurring
before this age are referred to as early-onset familial AD, with identifiable genetic links.
Other symptoms accompanying the memory loss are confusion, disorientation, anxiety,
delusions and apathy or depression (Terry & Katzman, 1983). As the disease advances,
symptoms may include anger, aggression, language problems, and impaired motor
function (Souren et al., 1995; Waldemar et al., 2007). In addition to the behavioral
disruptions associated with AD, several pathological changes have been observed in the
brain including beta-amyloid (Aβ) plaque deposition, neurofibrillary tangle formation,
and the progressive loss of cholinergic neurons (Bartus et al., 1982; Glenner & Wong,
1984; Masters et al., 1985; Arriagada et al., 1992; Goedert, 1996). These pathological
changes are the hallmarks of the disease, and may be responsible for the cognitive and
behavioral deficits exhibited in AD.
One of the most extensively investigated hallmarks of the disorder is the senile
plaques observed in post mortem examinations. Aβ proteins form the core of senile
plaques, one of the pathological changes which may be inducing the neuronal loss seen in
AD (Glenner & Wong, 1984; Masters et al., 1985). Senile plaques are extracellular
structures composed mainly of aggregated Aβ, and they are seen almost exclusively in
AD and AD-related pathologies like Down syndrome (Wisniewski et al., 1985). Several
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studies suggest that the accumulation of Aβ in the brain may initiate or lead to the
pathogenesis of AD (Selkoe, 2001). These findings and others have led to the amyloid
cascade hypothesis (Hardy & Higgins, 1992), which suggests that the amyloid deposits
that form plaques are the causative event in AD and the resulting neurodegeneration is a
by-product of this buildup. Evidence supporting this hypothesis comes from genetic
studies showing mutations in the genes associated with familial and late-onset AD lead to
increased Aβ aggregation and cognitive deficits (Goate et al., 1991; Murrell et al., 1991;
Corder et al., 1993; Levy-Lahad et al., 1995; Sherrington et al., 1995).
Investigators have been searching for genetic ties to AD for years in an attempt to
determine the etiology of the disease but with only mild success. Although a few genes
have been implicated as risk factors, none have yet provided a clear link between the
pathogenesis of AD and specific genetic targets, with most promising targets tied to
familial AD. Mutations in the amyloid precursor protein (APP), which is responsible for
the formation of Aβ peptides and whose encoding gene is located on chromosome 21,
have been linked to early-onset familial AD (Goate et al., 1991; Murrell et al., 1991).
Also, patients with Down syndrome, a trisomy (additional copy) of chromosome 21,
show AD pathology by 40 years of age (Holtzman et al., 1996). Alternative genetic
approaches have implicated mutations in genes called presenilins (PS) which have also
been tied to early-onset AD, specifically presenilin-1 (PS-1) and presenilin-2 (PS-2)
located on chromosomes 14 and 1, respectively (Levy-Lahad et al., 1995; Sherrington et
al., 1995). In AD, genetic investigations have implicated a specific allele of
Apolipoprotein E (ApoE), whose gene is localized on chromosome 19, which has been
linked to an increased likelihood of developing the disease (Corder et al., 1993).
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Although genetic linkage studies have provided useful insight into potential AD etiology,
genetic mutations related to Aβ can only account for a small percentage of AD cases. A
further limitation of the Aβ hypothesis is that many studies have indicated that there is
little to no correlation between the number or size of amyloid deposits and the severity of
the dementia, and that other pathologies seem to correlate better with the memory loss
seen in AD (Terry et al., 1991; Arriagada et al., 1992). Therefore, additional pathologies
such as the hyperphosphorylation of tau have been the focus of much research.
Neurofibrillary tangles (NFTs) are another neuropathological hallmark of AD and
are composed mainly of hyperphosphorylated tau, a protein that is associated with
microtubule stability and assembly. Tau hyperphosphorylation leads to the formation of
paired helical filaments (PHF) which are thought to lead to microtubule disintegration
and neuron death (Goedert, 1996). Because neurofibrillary pathology, as well as the
number of cortical tangles, correlates positively with the severity of dementia in AD
(Arriagada et al., 1992), it is of great interest to investigators of the disorder and those
developing pharmacological treatments. In addition, the regions of the brain that appear
to undergo the greatest degeneration of neurons and synapses in AD are those that project
to or from areas that have high densities of plaques and tangles, specifically the
hippocampus, neocortex, and basal forebrain (for review, see Kar et al., 2004). The latter
region contains large numbers of cholinergic neurons which project to the hippocampus
and cortex. Acetylcholine (ACh), principally an excitatory neurotransmitter, is important
for attentional processes, as well as learning and memory (Deutsch, 1971; Wenk et al.,
1994; Woolf, 1996). A reduction in neurons containing ACh has been consistently
observed in AD, particularly in the early stages of the disorder.
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Cholinergic cell loss is a hallmark of the neurodegeneration in AD, marked by a
progressive loss of ACh-containing neurons with a corresponding decline in cognitive
function (Perry et al., 1981; Terry et al., 1991). The cholinergic hypothesis of AD
postulates that the cognitive deficits in AD are caused by the early loss of cholinergic
basal forebrain (CBF) neurons (Bartus et al., 1982). This hypothesis is supported by
many studies which demonstrate that the loss of CBF neurons occurs early in the disease
progression, likely before a clinical diagnosis is reached (Bartus et al., 1982; Bowen et
al., 1982; Beach et al., 1997; Beach et al., 2000). Also, the severity of the dementia in AD
is highly correlated with the amount of cholinergic loss (Perry et al., 1981). Furthermore,
the first drugs to be developed for AD have targeted the cholinergic system with
moderate effectiveness. Donepezil, the first FDA-approved drug for AD and also the
most widely prescribed, has shown to be effective at ameliorating behavioral symptoms
associated with learning and memory in the early stages of the disease (Rogers et al.,
2000). Donepezil is an acetylcholinesterase (AChE) inhibitor, effectively reducing the
extent of the breakdown of ACh and increasing the available amount of ACh at the
synapse (Sugimoto et al., 1990). It has long been thought that AChE inhibitors only have
the ability to alleviate the symptoms of AD, but recent studies suggest they may have
disease-modifying effects as well (Sabbagh et al., 2006). One possible explanation as to
why these CBF neurons are dying is related to calcium levels and excitotoxicity (Lucas &
Newhouse, 1957).
Excitotoxicity results from the overload or overabundance of calcium ions in
neurons, and can be caused by the excessive activation of several receptors including
glutamate receptors (Lucas & Newhouse, 1957). This excessive receptor activation can
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lead to a large and persistent influx of calcium into the cell which produces too much
excitation that can lead to cell death. Excitotoxicity has been tied to several
neurodegenerative disorders including Huntington’s disease, amyotrophic lateral sclerosis
(ALS), and AD (Mattson et al., 1992; Taylor-Robinson et al., 1994; Cluskey & Ramsden,
2001). In AD specifically, increased calcium levels have been found in cells containing
NFT and may even precede tangle formation (McKee et al., 1990). Furthermore, Aβ
production is increased as a result of calcium influx in vitro (Querfurth & Selkoe, 1994).
An endogenous neuropeptide that seems to be effective at reducing excitotoxicity and
which has the capacity to protect neurons from overactivity (i.e. trophic properties) is
galanin (Cortes et al., 1990).
Galanin acts primarily as a neuromodulator in the central nervous system (CNS),
interacting with several neurotransmitters including ACh, serotonin (5-HT), glutamate,
and norepinephrine (Dutar et al., 1989; Pieribone et al., 1995; Kinney et al., 1998; Xu et
al., 1998). Galanin is also overexpressed in AD, hyperinnervating surviving CBF neurons
at concentrations as high as twice that of age-matched controls (Chan-Palay, 1988; Beal
et al., 1990). When administered into the lateral ventricles or hippocampus of rodents,
galanin has been shown to impair reference and working memory in several learning and
memory tasks, including the Morris water task, T-maze delayed alternation, delayed nonmatching to position, starburst radial maze and trace fear conditioning (Mastropaolo et
al., 1988; Robinson & Crawley, 1993; Ogren et al., 1996; Kinney et al., 2002; Kinney et
al., 2003). Based on these findings, it is possible that galanin is contributing to the
cognitive deficits observed in AD by inhibiting CBF neurons in an attempt to serve a
neuroprotective role. One important question that has not been directly investigated is
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whether galanin specifically modulating cholinergic tone may be responsible for the
learning impairments above, which would have large implications for galanin in AD.

Research Questions
The present study investigated in experiment 1 if donepezil, the aforementioned
AChE inhibitor, was able to rescue any of the cognitive impairment induced by central
galanin administration consistent with other investigations. Because galanin has been
shown to inhibit cholinergic signaling (Fisone et al., 1987), donepezil may be able to
reverse the galanin-induced deficit by increasing cholinergic tone. If donepezil is able to
rescue the learning and memory deficits in the galanin-infused animals, then it suggests
that galanin may produce a deficit by modulating cholinergic mechanisms. However, if
donepezil is unable to significantly rescue the galanin-induced deficit, it is likely the
learning and memory impairments produced by galanin are unrelated to its suppression of
cholinergic activity. Further, these data would also provide important information
regarding the galanin-induced deficit reported in other studies. Such findings would
indicate that galanin’s role in AD may not be as closely tied to the cholinergic system as
the literature suggests. Either way, the first part of our study would provide crucial
insight into galanin-ACh interactions, as well as perhaps answer some questions as to
galanin’s role in AD.
In experiment 2, we examined the effect that galanin and donepezil have on
learning and memory, individually as well as in combination, following administration of
the cholinergic neurotoxin, ethylcholine mustard aziridinium (AF64A). AF64A is a
selective cytotoxin which specifically targets cholinergic neurons and produces
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behavioral and histological deficits in the targeted region (for review see Smith, 1988).
The effects of a cholinergic lesion on spatial learning and memory have been quite
inconsistent with many studies finding a deficit while others have not (Walsh et al., 1984;
Lamberty et al., 1992; Nakamura et al., 1992; Opello et al., 1993; Dornan et al., 1996;
Bizon et al., 2003; Frick et al., 2004; Dashniani et al., 2009). The extent of the lesion and
the amount of toxin administered likely influence whether or not deficits are observed
following cholinergic-specific lesions. Our study utilized a relatively low dose of AF64A
in order to damage but not fully destroy the cholinergic system. Further, our intent was to
mimic the cholinergic loss observed in early or even pre-clinical AD necessitating a
smaller dose of the toxin.
We hypothesized that co-administration of donepezil and galanin following an
AF64A-induced cholinergic lesion would in part rescue any learning and memory deficits
caused by the toxin and potentially preserve a large number of cholinergic neurons. It
may be possible that following the cholinergic lesion, galanin may preserve some
cholinergic function, if it is in fact a trophic factor in vivo, and donepezil may
behaviorally offset the AF64A-induced loss of ACh. If donepezil and galanin together are
able to ameliorate the cognitive impairment and cell loss to a greater degree than just
donepezil alone, then this finding would lend significant support to the argument for
developing galanin agonists as an adjunctive treatment with donepezil in AD patients.
Alternatively, if donepezil and galanin administration fails to improve performance or
cholinergic neuron survival, this finding would suggest the utility of galanin antagonists
in AD (if the increase in survival is absent, galanin may simply be exacerbating the
cognitive impairment). Regardless of the findings, based on the overlap of the efficacy of
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donepezil to ameliorate AD symptoms and the overexpression of galanin in AD, this
investigation will contribute to the understanding of each of their roles in the disorder.
We are genuinely surprised that there is no literature along these lines and this
experiment should reveal insightful information about AD and the possible ways it can be
therapeutically treated in the future. Below we have outlined a more comprehensive
review of each of the aforementioned approaches and findings in AD.
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CHAPTER 2
REVIEW OF RELATED LITERATURE
Amyloid β Hypothesis
The Aβ protein accumulates extracellularly in AD resulting in the formation of
senile plaques, which may lead to cell damage and even cell loss. Aβ was first purified in
1984 from cerebrovascular amyloid protein by Glenner & Wong and from senile plaques
the next year by Masters et al. (1985), which was when its amino acid sequence was
determined. Various mechanisms have been suggested to account for the neurotoxicity of
Aβ peptides and senile plaques. Various studies have discovered a disruption in calcium
homeostasis following Aβ administration which could potentially lead to excitotoxicity
and cell loss. Further, it has been suggested that plaques may disturb surrounding
cytoskeletal elements by “squishing” nearby cells. Although the mechanism by which Aβ
contributes to neurodegeneration remains to be conclusively demonstrated, how the
peptide is formed has been better characterized.
Aβ is formed by the proteolytic processing of its precursor protein, APP. APP is
a membrane-spanning protein encoded for on chromosome 21. The APP gene product
appears to be involved with synaptic transmission, axonal transport, cell adhesion and
support, and cholesterol metabolism (for review, see Selkoe, 1994). Knockout
(elimination of the gene product) and knockdown (reduction in the relative amount of a
gene product) studies of APP have provided extensive information about its function.
APP seems to play a role in muscle development or function, and has also been
implicated in the formation of long-term potentiation (LTP), a cellular process argued to
be essential for learning (Douglas & Goddard, 1975; Kauer et al., 1988; Dawson et al.,
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1999; Seabrook et al., 1999; Senechal et al., 2008). Under normal conditions, the APP
protein is degraded via a series of events.
The proteolytic processing of APP results in Aβ fragments of varying length,
depending on where APP is cleaved by specific enzymes called secretases (Shoji et al.,
1992; Sisodia & Price, 1995). If APP is cleaved by alpha (α)-secretase, a soluble form of
APP (sAPP) is secreted which is readily absorbed and processed by lysosomal proteolytic
events. Cleavage by α-secretase occurs in the extracellular domain of APP within the Aβ
sequence, thus preventing the formation of longer, neurotoxic forms of the Aβ peptide
(Lannfelt et al., 1995). The senile plaques seen in AD are primarily made of the 40 and
42 amino acid Aβ peptides, with studies showing that the 42 amino acid Aβ is more
neurotoxic, i.e. more damaging to neurons, than the shorter variants (Roher et al., 1996).
If APP is cleaved by beta (β) and gamma (γ)-secretases, this leads to formation of an Aβ
peptide 39-43 amino acids long, which is similar to the lengths of Aβ predominantly
found in senile plaques in AD (Golde et al., 1992; Citron et al., 1996).
Initially, β-secretase (i.e. BACE) cleaves APP at its amino-terminus in the
extracellular domain which is followed by cleavage by γ-secretase within the
transmembrane domain (Vassar et al., 1999). BACE-1 inhibitors have been demonstrated
to inhibit β-cleavage of APP and effectively lower Aβ levels in vitro and in vivo (Hussain
et al., 2007). Inhibitors of γ-secretase have also been shown to reduce Aβ levels in the
brain when administered to mice that overexpress a human mutant version of APP
(Dovey et al., 2001). Inhibition of either of these two secretases theoretically leads to a
reduction in the amount of Aβ because both β- and γ-secretase are necessary in order to
cleave APP in a fashion that yields the 39-43 amino acid peptides known to aggregate
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and form plaques. Considerable pharmacological research is being directed at developing
β- and γ-secretase inhibitors as therapeutic targets in an effort to reduce plaque load and
perhaps even halt the progression of the disease. A great deal of research has also been
conducted examining the genetic underpinnings of AD with a particular focus on genes
tied to the proteolytic processing of Aβ.
Genetic linkage studies have tied familial forms of AD to the gene for APP on
chromosome 21 (Goate et al., 1991; Citron et al., 1992). Over twenty mutations in the
gene have been identified to date that are thought to be responsible for the familial earlyonset form of the disease (Chai, 2007). Individuals with any of these mutations have a
slightly increased chance, compared to the population as a whole, of developing earlyonset AD because they have a greater amount of APP and thus produce more Aβ than
normal individuals (Citron et al., 1992; Suzuki et al., 1994). Interestingly, almost all APP
mutations are located within or adjacent to the Aβ peptide region of the precursor protein,
and thus may affect the proteolytic processing of APP (Schellenberg, 1995). Related to
the processing of APP are the presenilin (PS) genes which have also been implicated in
autosomal dominant familial AD.
Presenilins have been linked to early-onset AD, specifically PS-1 on chromosome
14 and PS-2 on chromosome 1 (Levy-Lahad et al., 1995; Sherrington et al., 1995).
Similar to the aforementioned mutations in APP, PS mutations lead to increased Aβ
production, especially production of Aβ42, a species of the peptide known to be most
toxic to neurons and overabundant in AD (Iwatsubo et al., 1994; Duff et al., 1996; Citron
et al., 1997). Investigations into PS mutations and Aβ deposition have shown that
mutations in the PS gene increase the ratio of Aβ42 versus Aβ40 as compared to non-PS
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mutant cases of AD (Borchelt et al., 1996). This shift in the production of Aβ42 can have
significant consequences, as many studies have suggested that Aβ42 aggregates more
readily than Aβ40 and is deposited early in the formation of plaques (Jarrett et al., 1993;
Iwatsubo et al., 1994). Furthermore, PS mutations seem to alter APP or Aβ processing by
increasing the amount of cleavage by γ-secretase, and thus increasing the amount of
insoluble Aβ released (DeStrooper et al., 1998; Wolfe et al., 1999). Knockout studies
with animals that do not express the PS-1 and PS-2 genes show an abolishment of γsecretase mediated cleavage of APP (Steiner et al., 1999; Yu et al., 2001).
Based on these findings and others, Wolfe et al. (1999) proposed the hypothesis
that PS itself is a γ-secretase, an intramembranous protease that is responsible for γcleavage of APP. Despite further evidence supporting this hypothesis, it appears that PS
and γ-secretase are not the same protein even though they are highly related (Takasugi et
al., 2003). Also, although PS-knockout mice seem to exhibit a complete abolishment of
γ-secretase activity, these animals still produce Aβ42 peptide fragments, suggesting there
are additional enzymes with activity similar to γ-secretase (Wilson et al., 2002). While
the discovery that these three genes (APP, PS-1, and PS-2) are linked to familial AD
advanced the investigation of the disorder, it is important to recognize that they
collectively only account for about 10% of all familial early-onset cases (Cruts et al.,
1998). Given that more than 95% of AD cases occur after the age of 60, it is clear that
these genetic mutations contribute only minimally to the risk of developing the more
common variant of the disease (Holmes, 2002). With that said, much more is known
about the genetics of familial early-onset AD than about sporadic, late-onset AD.
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One gene implicated in non-familial forms of AD is the gene coding for
Apolipoprotein E (ApoE). ApoE is a protein critical in regulating brain Aβ peptide levels
and trafficking lipids throughout the brain (for review, see Holtzman, 2001). ApoE is
responsible for clearing Aβ peptides from the brain across the blood-brain barrier into the
peripheral circulation (LaDu et al., 1994; LaDu et al., 1995; Morikawa et al., 2005). Aβ
peptides are normally generated at very high levels in the brain and are cleared at an
equivalent rate (Bateman et al., 2006). Thus, even small reductions in the clearance of Aβ
could result in elevated levels of Aβ peptides and eventual plaque formation. The
lipidation status of ApoE appears to be important with regard to how well it can bind to
Aβ and clear the peptide from the brain (Tokuda et al., 2000). If ApoE is in a lipidated
form, it is more effective at clearing Aβ than if it is non-lipidated.
Another way that Aβ is cleared from the brain is through a proteolytic mechanism
involving either neprilysin (NEP) (Iwata et al., 2000) or insulin-degrading enzyme (IDE)
(Kurochkin & Goto, 1994). Inhibition of either of these proteinases leads to a substantial
elevation of Aβ levels in the brain and increased plaque deposition (Dolev and
Michaelson, 2004). Recent research suggests that ApoE facilitates these enzymes,
allowing them to degrade Aβ (Jiang et al., 2008). The ability of ApoE to clear Aβ is also
dependent upon the isoform or allele of ApoE (Corder et al., 1993).
ApoE has three alleles: ApoE-ε2, ApoE-ε3, and ApoE-ε4, with one or two copies
of the ε4 allele leading to an increased risk of developing AD (Corder et al., 1993).
Studies with transgenic mice overexpressing APP have demonstrated ApoE isoformspecific effects on the ability of each allele to clear Aβ from the brain. The most effective
allele at eliminating Aβ is the ε2 allele, followed by the ε3 allele, with the least effective
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being the ε4 allele (Holtzman, 2004). Thus, individuals with one or two ε4 alleles (two
alleles being the least effective possible form) of ApoE have a less effective mechanism
for clearing Aβ from the brain, resulting in increased levels of the peptide (Saunders et
al., 1993). In fact, a genetic study done by Corder et al. (1993) showed that over 90% of
subjects examined who had two copies of the ε4 allele (4/4) had AD. Almost 50% of
subjects with one copy of the ε3 and one copy of the ε4 (3/4) were affected with AD.
Only about 20% of subjects with no copies of the ε4 allele (2/2, 3/3, or 2/3) had the
disease. Corder et al. (1993) also looked at the average age of onset in individuals with
one or two copies of the ε4 allele. The authors found that expression of it leads to a
significantly earlier age of onset, with two copies of the ε4 allele leading to an earlier
onset than just one copy. While the discovery of the ApoE gene and its relation to Aβ is
critical to understanding AD pathogenesis, it is not a determinant of the disease and it
must be regarded carefully. A consequence of the Aβ pathology that arises due to these
mutations may be an initiation of the inflammatory response, a common neurological
occurrence in individuals with AD.
Glial cells in the brain, specifically microglia and astrocytes, can serve as
mediators of the inflammatory response when necessary, defending the CNS from
pathogens and aiding in the recovery from damage and stress (reviewed in Skaper, 2007).
AD brains exhibit extensive localized activation of both microglia and astrocytes in
response to neuronal and synaptic damage and Aβ accumulation (reviewed in Akiyama et
al., 2000). It is likely this inflammation related to AD pathology may be both beneficial
as a mechanism to promote neuronal survival and detrimental to AD brain function and
the degeneration process (Wyss-Coray & Mucke, 2002). Recent studies have shown that
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aggregated Aβ is itself capable of activating the inflammatory response by activating
microglia and enhancing the synthesis and release of proinflammatory cytokines (Tan et
al., 1999; Combs et al., 2001). These proinflammatory cytokines may also accelerate tau
pathology and NFT formation, perhaps linking Aβ-induced inflammation and
neurofibrillary pathology (Sheng et al., 2000; Quintanilla et al., 2004; Guo et al., 2006).
This finding would suggest that inflammation is actually advancing AD pathology and
accelerating the neuronal loss. Although microglial activation in AD may be caused by
Aβ pathology, microglial activity correlates more closely with NFT pathology (Hayes et
al., 2002). This relationship suggests that although Aβ may trigger the initial activation of
microglia, the resulting inflammatory response may be more directly related to tau
pathology (Blurton-Jones & LaFerla, 2006). Another study done by Guo et al. (2006)
suggests that soluble Aβ and tau may directly interact to promote each other’s
aggregation. In fact, it has been demonstrated that in vitro injection of Aβ activates GSK3β, one of the enzymes thought to be responsible for phosphorylating tau (Lovestone et
al., 1996). Thus, it is clear there is some relation between Aβ and tau pathology, but more
studies are needed to clarify the connection.
Much of the above research eventually led to the amyloid cascade hypothesis
which suggests that abnormal Aβ production and accumulation triggers the
neurodegeneration seen in AD. Hardy & Higgins (1992) proposed that deposition of Aβ
protein is the causative factor in AD pathology and that the NFT, neuronal loss, and
dementia that follow are a result of this deposition. They hypothesized that neurotoxic Aβ
peptides disrupt calcium homeostasis extracellularly and disrupt calcium concentrations
intracellularly. This intra-neuronal increase in calcium concentration could potentially be
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what causes tau proteins within the cell to be hyperphosphorylated and form PHF, which
are the primary component of NFT. Thus, for this interpretation of the amyloid cascade
hypothesis to be correct, elevations in Aβ levels should cause hyperphosphorylation of
tau and neurofibrillary pathology to develop. This link between Aβ and tau has been
verified to some extent in animal models and in cell culture, wherein Aβ causes an
increase in tau phosphorylation (Gotz et al., 2001; Lewis et al., 2001; Zheng et al., 2002).
Transgenic mice harboring mutations in both human APP and human Tau, as well as a
mutant PS-1 allele, dubbed 3xTg-AD mice, develop both Aβ deposits and NFT-like
pathology (Oddo et al., 2003a). Studies using these mice have demonstrated that Aβ
accumulation precedes the development of tau pathology by several months, further
suggesting Aβ may promote tau phosphorylation and aggregation (Oddo et al., 2003b).
Despite the amount of research supporting the amyloid cascade hypothesis, there
are several gaps between the hypothesis and data collected. First, the hypothesis is
inconsistent with the presence of senile plaques in normal aged brains similar to those
seen in AD (Crystal et al., 1988; Katzman et al., 1988; Price et al., 1991). If Aβ deposits
are the catalyst for AD neurodegeneration, then we would not see individuals with no
cognitive impairment and diffuse plaque load. Secondly, in transgenic animals that
overexpress either APP or one of the PS mutations, there is no significant NFT formation
or neurodegeneration despite considerable Aβ plaque load (Hsiao et al., 1996; Takeuchi
et al., 2000). Because no AD-like pathology develops in these mice except for the
plaques, it is difficult to argue that Aβ is directly causing the significant neuronal loss
seen in the disease. Another limitation of the amyloid cascade hypothesis is that
neurodegeneration and dementia occur in the absence of Aβ plaques in several diseases
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related to the tau protein (Hutton et al., 1998; Spillantini et al., 1998). Regardless of
whether or not Aβ peptides are the causative agent in AD, it is likely that they contribute
to the cognitive symptoms seen in the disease, as well as have some effect on the
pathogenesis in AD. Another pathogenic contributor to the neurodegeneration observed
in AD is the tau protein which is hyperphosphorylated resulting in NFTs and neuronal
loss.

Tau Hypothesis
Tau is an intracellular protein found abundantly in the central and peripheral
nervous systems and is critical for microtubule stability and assembly, as well as
microtubule flexibility (Goedert et al., 1989; Goedert et al., 1992). Microtubules are
located throughout the neuron and in the axon and are essential for neurotransmission,
axonal transport and axonal support (Paulson & McClure, 1974; Weingarten et al., 1975;
Kraemer et al., 2003). Tau is a phosphoprotein which implies that it requires
phosphorylation, or the addition of a phosphate group, in order for it to become activated
(Butler & Shelanski, 1986). Tau is partially phosphorylated in the normal brain and this
phosphorylation may regulate microtubule stability and assembly. This microtubule
regulation appears to happen by reducing tau’s binding to tubulin, a protein that makes up
microtubules, and reducing the promotion of microtubule assembly (Hasegawa, 2004).
Thus, the phosphorylation of tau plays a pivotal role in regulating microtubule production
by reducing the amount of microtubule assembly and decreasing the ability of tau to bind
to tubulin.
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In AD, the tau protein is hyperphosphorylated, which leads to the destruction of
microtubule assemblies via the aforementioned mechanisms (Grundke-Iqbal et al., 1986).
The degradation of microtubules may cause impaired axonal transport and possibly cell
death (Kosik et al., 1986). Tau hyperphosphorylation renders tau unable to bind to
microtubules, an event proposed to be responsible for self-assembly into the paired
helical filaments (PHFs) (Goedert et al., 1988; Bramblett et al., 1993; Yoshida & Ihara,
1993). These PHFs, which are primarily made up of hyperphosphorylated tau, correlate
strongly with neuronal death in AD (Gomez-Isla et al., 1997). Also, whereas Aβ
pathology is relatively specific to AD, NFT formation occurs in other diseases/disorders
related to tau, collectively referred to as tauopathies.
In 1998, several mutations in the tau gene were discovered in families with
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), a
related but distinct neurodegenerative disease, indicating genetic evidence that tau
abnormalities may be sufficient to lead to neurodegeneration (Hong et al., 1998; Hutton
et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998). This discovery led to the
production of many different transgenic lines of mice with tau mutations. One specific
line, the P301L mice, shows significant age-dependent NFT formation, memory
impairment, and neuron loss (Lewis et al., 2000; Ramsden et al., 2005). Although there is
significant neurodegeneration in these animals, they do not develop any Aβ pathology,
implying that tau mutation or tangle formation is not sufficient on its own to cause senile
plaques in an animal model of AD. These findings provide strong evidence that tau may
induce neuronal loss in the absence of Aβ, but also suggest that Aβ plaque formation may
lie upstream of tau, at least for AD.
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Consistent with the findings that Aβ plaque burden does not correlate well with
the severity of dementia, but NFT formation does, is the finding that NFTs can be
differentiated into neuropathological stages in AD. Braak & Braak (1991) reported
detailed pathological studies about the distribution of plaques and tangles in autopsy
brains of demented and non-demented individuals. They showed that Aβ deposition was
of little significance in relation to neuropathological staging, whereas NFTs exhibited a
neuroanatomical distribution pattern permitting the differentiation of six stages of disease
progression in AD. Tangles are first observed in the entorhinal cortex where neuronal
loss occurs the earliest, and are closely related to the initial memory impairment in AD,
whereas Aβ deposits are not found in the hippocampal formation until the late stages of
the disease (Hasegawa, 2004). Another post-mortem study showed that both NFTs and
neuronal loss increased in parallel with the duration of AD, although the amount of
neuronal loss was five or six times larger than the amount of tangle accumulation
(Gomez-Isla et al., 1997). In contrast, the authors also found that the amount of plaques
and Aβ accumulation were not related to neuronal loss, the number of NFTs, or the
duration of the disease.
Despite the recent attention the tau hypothesis has received, it has limitations
similar to the Aβ hypothesis. Foremost is the finding that NFTs are extremely common
and perhaps universal in the nucleus basalis of Meynert, a basal forebrain region rich in
cholinergic fibers, in non-demented aged individuals (Beach et al., 1998). Secondly,
because animal models of tauopathies fail to develop Aβ pathology or the global neuronal
loss seen in AD, it is difficult to claim that tau aggregation and NFTs are causing the
disease. Another possible explanation for the significant neuronal loss and degeneration
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seen in AD is related to the cholinergic hypothesis and the loss of cholinergic neurons in
areas important for learning and memory.

Cholinergic Hypothesis
The cholinergic deficit in AD is the earliest and most frequently reproduced
finding, specifically the profound reduction in choline acetyltransferase (ChAT) activity
(Davies & Maloney, 1976; Bowen et al., 1982). ChAT is the enzyme responsible for
synthesizing acetylcholine (ACh), and its decreased activity leads to reduced amounts of
available ACh in the brain, specifically in the hippocampus and neocortex (Perry et al.,
1977; Davies, 1979). The finding that cholinergic cell loss is associated with the presence
of plaques in non-demented aged individuals suggests that the loss of cholinergic neurons
precedes the clinical diagnosis of AD (Beach et al., 1997). Furthermore, studies indicate
that the severity of the dementia in AD correlates well with the extent of cholinergic loss
and the reduction in ChAT activity in the cortex (Perry et al., 1981). Cholinergic loss
occurs first and foremost in the basal forebrain where CBF neurons deteriorate very early
in the disease progression (Whitehouse et al., 1982; Bowen et al., 1982; Beach et al.,
2000). ACh has been implicated in different cognitive functions such as learning and
memory (Whitehouse, 1967; Cox & Tye, 1973; Valentino & Dingledine, 1981; Spencer
& Lal, 1983; Spencer et al., 1985; Woolf, 1996). Once ACh is released, it can bind to
either of two receptor subtypes: nicotinic acetylcholine receptors or muscarinic
acetylcholine receptors (Role & Berg, 1996; reviewed in Wevers & Schroder, 1999 and
Ishii & Kurachi, 2003).
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Nicotinic receptors are ionotropic receptors (receptors that can open ion channels
when ACh binds to them) while muscarinic receptors are metabotropic receptors
(receptors that activate a G-protein and trigger intracellular events when ACh binds,
including the opening of multiple ion channels). There appears to be a selective loss of
ACh receptors in the cortex and hippocampus in AD, and it seems to be more pronounced
for nicotinic receptors (Flynn & Mash, 1986; Perry et al., 1995; Wevers et al., 2000).
Nicotinic receptor activation using nicotine produces a significant increase in the
amount of phosphorylated tau both in vitro and in 3xTg-AD mice (Hellstrom-Lindahl et
al., 2000; Oddo et al., 2005). The exact mechanism of how this increase in
phosphorylation occurs remains unclear, but it may be a result of increased calcium levels
due to overactivation of the nicotinic receptors. Nicotonic receptors are one of only a few
ionotropic receptors in the brain that allow an influx of calcium ions when ACh binds
(McGehee et al., 1995; Role & Berg, 1996). This increase in intracellular calcium may
activate different calcium-dependent kinases, such as GSK3β or p38MAP kinase, which
may be responsible for phosphorylating tau (Oddo et al., 2005). Nicotinic receptor
activation also appears to have an effect on Aβ deposits in the brain. In vitro studies have
shown that nicotine seems to inhibit Aβ fibril formation and also disrupts already formed
fibrils (Salomon et al., 1996; Zeng et al., 2001; Ono et al., 2002). This would suggest that
in the absence of ACh, the formation of fibrils is allowed to progress at a more rapid rate.
Studies using transgenic mice, specifically mice that overexpress human APP called
Tg2576, showed a dramatic decrease both in Aβ plaque burden and the levels of
insoluble Aβ40 and Aβ42 after chronic administration of nicotine for a period of five and
a half months (Nordberg et al., 2002). It is difficult to determine what effect the loss of

21

nicotinic receptors has on tau phosphorylation and Aβ deposits in AD, and more studies
are necessary to elucidate the relationships.
Muscarinic receptors, specifically the M1 receptor subtype, are highly expressed
in the cerebral cortex and hippocampus, and seem to be particularly relevant to memory
function in AD (Anagnostaras et al., 2003). The M1 receptor has been shown to decrease
tau phosphorylation suggesting that decreased cholinergic activity may lead to
destabilization of the microtubule network and eventual tangle formation. In vitro studies
using cholinergic M1 agonists showed that the muscarinic-activated decrease of tau
phosphorylation was both time and dose dependent (Sadot et al., 1996). In vivo studies
using 3xTg-AD mice also showed a reduction in tau phosphorylation after administration
of a muscarinic agonist and conversely showed increased tau phosphorylation after
treatment with an M1 antagonist (Caccamo et al., 2006). Previous in vitro findings found
that M1 receptor agonists decrease tau phosphorylation by the reduction of GSK3β
activity (Forlenza et al., 2000), which appears to be the mechanism by which tau
phosphorylation was decreased in the 3xTg-AD mice. Muscarinic receptor activation also
appears to reduce Aβ production and increase the secretion of soluble APP (Buxbaum et
al., 1992). In the 3xTg-AD mice, an M1 agonist reduced Aβ deposition in the
hippocampus and cortex, and ameliorated cognitive deficits in a spatial memory task
(Caccamo et al., 2006). This finding that muscarinic activation regulates APP processing
(Nitsch et al., 1992) formed the basis for the hypothesis that AChE inhibitors may slow
disease progression by reducing Aβ production (Inestrosa et al., 1996).
AChE inhibitors were developed as a result of the cholinergic hypothesis in order
to increase cholinergic tone in individuals with AD (Davis et al., 1978; Bartus, 1979;
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Bartus et al., 1982). AChE is primarily responsible for the breakdown of ACh into
choline and acetic acid. AChE has also been implicated in Aβ plaque formation and
appears to have the ability to accelerate Aβ formation and deposition in AD (Inestrosa et
al., 1996). Therefore, by inhibiting the enzymatic activity of AChE, it may be possible to
reduce Aβ plaque formation and ameliorate AD symptomology. AChE inhibitors increase
the amount of ACh available in the synapse as well as enhance and prolong its action on
ACh receptors (Harvey & Rowan, 1990). AChE inhibitors have been approved for use in
mild to moderate AD and have been shown to improve cognitive deficits (Rogers et al.,
1998; Rosler et al., 1999; Tariot et al., 2000). One of the most widely prescribed and used
AChE inhibitors is donepezil.
Donepezil hydrochloride is a piperidine-based, non-competitive, reversible
inhibitor of AChE with high central nervous system specificity and a long duration of
action (Yamanishi et al., 1991). It has been demonstrated to be a well-tolerated drug that
improves cognitive performance and global function in mild to moderate AD patients
(Rogers et al., 1996; Rogers et al., 1998). Donepezil significantly increases extracellular
ACh concentrations both dose- and time-dependently (Kosasa et al., 1999). Furthermore,
donepezil was able to significantly improve a deficit in spatial learning and memory
induced in rats with lesions of the medial septum, a pathway by which cholinergic
neurons project to the hippocampus, at a relatively low dose of 0.5 mg/kg. The rescue of
the spatial deficit was almost to the level of the control animals in a Morris water maze
(MWM) spatial learning task (Ogura et al., 2000). Scopolamine, a cholinergic antagonist,
has been shown to produce learning impairments in rodents (Ogren et al., 1998; Elvander
et al., 2004). Donepezil, once again at a low dose of 0.5 mg/kg, was able to significantly
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decrease the scopolamine-induced deficit in rats in an 8-arm radial arm maze, a spatial
learning and memory task (Ogura et al., 2000).
Many animal models of AD show Aβ pathology and a few even show tau
pathology, but thus far none have been able to replicate the global neuronal loss exhibited
in AD. Nevertheless, administration of donepezil to different AD models provides
valuable insight into the cellular and molecular effects of the drug, as well as examines
the effect it has on behavioral deficits. One such animal model involves lesions of the
entorhinal cortex, a part of the brain which provides inputs to the hippocampus, using
ibotenic acid, a compound that produces non-specific excitotoxic lesions. Although the
lesion does not model the specific cholinergic loss which is a hallmark of AD, it is a
valuable tool to study hippocampal learning and memory deficits. One study
administered donepezil following an ibotenic acid lesion and found that donepezil was
able to partially rescue the lesion-induced deficit in the MWM (Spowart-Manning & van
der Staay, 2005).
Further animal models are the Tg2576 mice and APP23 mice that overexpress
human APP containing the Swedish double mutation and display age-related cognitive
deficits and plaque load (Hsiao et al., 1996; Sturchler-Pierrat et al., 1997; Kelly et al.,
2003). Briefly, the gene coding for APP is mutated to overexpress the protein and the
mice eventually develop Aβ plaques around 6 months of age (Sturchler-Pierrat et al.,
1997). A study with the Tg2576 mice showed that donepezil administration dosedependently (0.1, 0.3, or 1.0 mg/kg) reduced the cognitive deficit in a spatial memory
task (Dong et al., 2005). Another study investigated the effect of donepezil administration
(0.3 mg/kg) in the APP23 transgenic mice and found that it was able to rescue some of
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the deficits in the MWM (Van Dam et al., 2005). In a follow-up study using the APP23
mice, Van Dam et al. (2008) found that donepezil may have disease-modifying effects.
After chronic donepezil treatment (0.27 mg/kg per day for 8 weeks), animals experienced
a 3 week wash-out period where no drug was given in order to determine if treatment was
able to improve spatial memory in the MWM after the drug was no longer active.
Donepezil significantly improved performance of the APP23 mice both in acquisition and
retention of spatial memory in the MWM. This possible disease-modifying effect of
donepezil may be due to the relation between AChE and Aβ formation that we previously
reviewed. Because AChE has been implicated in amyloid plaque formation (Inestrosa et
al., 1996), the inhibition of AChE may lead to reduced Aβ pathology. In fact, donepezil
in vitro reduced AChE-induced Aβ aggregation by 22% (Bartolini et al., 2003). Further
evidence from in vitro studies found donepezil, but not other AChE inhibitors, had
neuroprotective effects on cell culture models of neuronal injury (Akasofu et al., 2008).
Another possible explanation for donepezil’s possible disease-modifying ability
is that in addition to its action on AChE, it antagonizes N-methyl-D-aspartate (NMDA)
receptors in the brain (Wang et al., 1999; Moriguchi et al., 2005). NMDA receptors are
activated by glutamate, an excitatory neurotransmitter, and when NMDA is open it
allows calcium ions into the cell. An overabundance of calcium ions can lead to
excitotoxicity and neuronal death which is what may be occurring in AD (Lucas &
Newhouse, 1957; Mattson et al., 1992). Thus, because donepezil is able to reduce the
activity of the NMDA receptor, it also may reduce excitotoxicity. This excitotoxic
inhibition may be mediated through nicotinic ACh receptors followed by specific kinases
which reduce NMDA receptor activity (Takada-Takatori et al., 2006). Interestingly,
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donepezil has also been found to improve cognitive performance in healthy young rats
(Cutuli et al., 2008), which suggests donepezil may act as a cognitive enhancing drug in
normal animals as well as in animals with cognitive deficits.
Donepezil is clearly able to ameliorate deficits related to AD pathology in early
and middle stages of the disease in AD patients and in animal models (Rogers et al.,
2000). It increases cholinergic tone and activity, likely compensating for the profound
deterioration of CBF neurons in AD. These findings also indicate why in the latter stages
of AD donepezil has been found to be less effective, as the overall loss of cholinergic
neurons may progress to a level beyond the capacity of an AChE inhibitor to improve.
Although it is not yet evident why these CBF neurons begin dying in AD, one possible
explanation is related to calcium levels and excitotoxicity.

Excitotoxicity Approach
Glutamate is an excitatory neurotransmitter pervasively expressed throughout the
central nervous system (Harvey & McIlwain, 1968). It can act on either ionotropic
receptors such as AMPA, kainate or NMDA receptors, or metabotropic receptors which
are coupled to G-proteins (Ishida & Neyton, 1985; O’Brien & Fischbach, 1986; CullCandy & Usowicz, 1987; Jahr & Stevens, 1987). Binding of glutamate to NMDA
receptors leads to an influx of calcium and excitation (MacDermott et al., 1986). Because
glutamate is a potent excitatory transmitter, excessive amounts or prolonged release can
elicit excessive excitation in neurons that may lead to cell death (Lucas & Newhouse,
1957; Olney & Ho, 1970). Chronic exposure to moderately elevated glutamate levels or
hyperactivity of glutamate receptors, which is what may be occurring in many
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neurodegenerative diseases as well as cerebral ischemia, can lead to a steady influx of
calcium which has been shown to be toxic for the cell (reviewed in Mattson & Chan,
2003). This calcium-induced cell death, also called excitotoxicity, has been investigated
in AD and may play a role in the progressive degeneration of neurons.
Calcium levels in AD appear to be elevated, potentially resulting in excitotoxicity
and cell death (Peterson et al., 1985; Peterson & Goldman, 1986). Calcium levels are
increased in neurons that contain NFTs as compared with tangle-free neurons (Murray et
al., 1992). The increased levels of calcium may precede tangle formation based on the
finding that levels of calcium/calmodulin-dependent protein kinase II (CamKII), the most
abundant kinase in the brain and dependent on calcium for activation, are increased in
hippocampal neurons which are vulnerable to degeneration (McKee et al., 1990).
Calcium levels may also be affected by Aβ peptides. In vitro studies show that
application of Aβ peptide increases the vulnerability of cortical neurons to glutamate
toxicity (Mattson et al., 1992). In vivo, the toxicity caused by Aβ injection into the
hippocampus or nucleus basalis of Meynert is reduced by NMDA antagonists, showing
that the toxicity is in part related to glutamatergic activity (Harkany et al., 1999; MiguelHidalgo et al., 2002). These studies suggest that glutamate receptor activation and
exposure to Aβ peptides together are more injurious than either insult alone (Canzoniero
& Snider, 2005). In addition to increasing vulnerability to calcium influx through
glutamate receptors, specifically NMDA, Aβ can also increase resting calcium levels
both intra- and extracellularly (Mattson et al., 1992). In an attempt to address the
excitotoxic damage caused by increased calcium levels and overactivity of glutamate
receptors, NMDA-receptor antagonists have been developed.
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Memantine is an uncompetitive NMDA antagonist that has been approved for use
in moderate to severe cases of AD dementia (Ditzler, 1991; Winblad & Poritis, 1999;
Tariot et al., 2004). What makes memantine an uncompetitive antagonist is that it
becomes more effective at blocking NMDA receptors the more the receptors become
activated. In other words, under normal physiological conditions, the NMDA receptor
will not be antagonized by memantine because the drug will remain inactive. When the
NMDA receptor is overactivated by glutamate, memantine becomes extremely effective
at returning NMDA activity to a normal state. At a fixed concentration of memantine, its
ability to block the NMDA receptor increased as the concentration of NMDA increased
(Chen et al., 1992). For this reason memantine is usually only administered in later stages
of AD when calcium concentrations may be sufficiently elevated and the drug is able to
exert its unique uncompetitive NMDA blockade. Another way of possibly reducing the
excitotoxicity seen in AD is via the endogenous peptide galanin, which has been shown
to exhibit neuroprotective effects.

Galanin Literature
Galanin is a 29 amino acid (30 in humans) neuropeptide, first isolated from
porcine intestine by Tatemoto et al. (1983). It is widely expressed throughout the
mammalian nervous system with galaninergic neurons in areas such as the cerebral
cortex, nucleus basalis of Meynert, hippocampus, amygdala, and locus coeruleus
(Kordower et al., 1992; Perez et al., 2001). Galanin inhibits several classical
neurotransmitters including glutamate, serotonin, norepinephrine, and ACh (Dutar et al.,
1989; Pieribone et al., 1995; Robinson et al., 1996; Kinney et al., 1998; Ogren et al.,
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1998; Xu et al., 1998). In the basal forebrain of rodents, galanin co-localizes with
cholinergic neurons within the medial septum/diagonal band complex (Melander et al.,
1985; Melander et al., 1986; Miller et al., 1998). In the human basal forebrain, there
exists a small population of non-cholinergic galaninergic interneurons and a dense
galaninergic fiber plexus that innervates CBF neurons (Mufson et al., 1993; Bowser et
al., 1997). In fact, it was found that galanin immunoreactivity is present in ~50-70% of
CBF neurons (Melander et al., 1985). These findings led to the hypothesis that galanin
may mediate the cholinergic system related to cognitive function (Mufson et al., 1998). In
vitro studies have demonstrated that galanin reduces ACh release and ACh-elicited
excitation and also inhibits LTP in hippocampal neurons (Fisone et al., 1987; Dutar et al.,
1989; Palazzi et al., 1991; Sakurai et al., 1996). A different in vitro study found that
galanin actually has the ability to excite cholinergic neurons, but further studies are
needed to clarify this excitatory role for galanin (Jhamandas et al., 2002). In vivo work
has shown that galanin administered into the hippocampus, lateral ventricles, or basal
forebrain impairs cognitive performance on spatial learning and memory tasks in rats
(McDonald et al., 1998; Wrenn & Crawley, 2001; Kinney et al., 2003). Furthermore,
mice that overexpress galanin (GalOE) display cognitive deficits characteristic of AD
(Steiner et al., 2001). Taken together, these data suggest that galanin may inhibit the basal
forebrain and hippocampus to regulate cognitive processes.
Alternatively, galanin also appears to play a neurotrophic or neuroprotective role
in the brain (Holmes et al., 2000; O’Meara et al., 2000; Mahoney et al., 2003; Elliot-Hunt
et al., 2004; Elliot-Hunt et al., 2007). Following trauma or injury to the central nervous
system, galanin expression is up-regulated in many brain regions (Cortes et al., 1990).
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Galanin also acts as a survival and growth-promoting factor to neurons in both the central
and peripheral nervous systems (Holmes et al., 2000; O’Meara et al., 2000; Mahoney et
al., 2003). Zini et al. (1993) found that galanin reduces glutamate release by 50-60% in
rat hippocampal slices. Because glutamate is the principle excitatory neurotransmitter in
the brain, and it can be responsible for calcium-induced excitotoxicity, the ability of
galanin to reduce glutamate release classifies it as a trophic factor. Elliot-Hunt et al.
(2004) also found that galanin promotes hippocampal neuron survival in a number of in
vitro models of excitotoxic injury. Using hippocampal slices from transgenic animals
either over-expressing galanin (GalOE) or galanin knockout (GalKO), galanin was shown
to exert a protective effect after administration of glutamate or staurosporine, an agent
which inhibits protein kinase activity and can lead to apoptosis, or programmed cell
death. Galanin has also been shown to protect neurons from the toxic effects of Aβ in
vitro, further exhibiting its neuroprotective capacity (Ding et al., 2006). Due to this
ability to reduce excitotoxic damage and protect from neuronal injury, galanin agonists
have significant implications as anti-epileptic agents. In order to further understand
galanin and its possible therapeutic effects, we must first examine its receptors which
would ultimately be the targets of any drugs.
Galanin receptors are G-protein-coupled metabotropic receptors, which activate
second messenger pathways after the binding of a ligand (Hulting et al., 1993; Walli et
al., 1994; Branchek et al., 1998). The first galanin receptor (GAL-R1) is a Gi/o coupled
receptor, which belongs to a family of receptors with mostly inhibitory actions. GALR1’s are found throughout the human brain, particularly in the cortex, hippocampus,
thalamus, and amygdala (Habert-Ortoli et al., 1994). Activation of GAL-R1 leads to
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inhibition of adenylyl cyclase and cyclic adenosine monophosphate (cAMP), both of
which are signal transduction mechanisms crucial for learning and memory processes,
especially consolidation of memory (Palazzi et al., 1991; Karelson & Langel, 1998;
Wang et al., 1998; Iismaa & Shine, 1999; Kinney et al., 2003).
The second galanin receptor subtype (GAL-R2) can be of a Gq subtype or a Gi/o
subtype, and can be either excitatory or inhibitory (Fathi et al., 1998; Wittau et al., 2000).
GAL-R2’s are found in areas of the human brain similar to GAL-R1’s including the
cortex, hippocampus, amygdala, thalamus, and cerebellum (Borowsky et al., 1998; Fathi
et al., 1998). A key difference between the two receptor subtypes which may explain
their different mechanisms of action is that they are found in different parts of the
hippocampus and exert different effects when activated. The ventral hippocampus
contains significantly more GAL-R1’s than the dorsal hippocampus which contains more
GAL-R2’s (Melander et al., 1985; Melander et al., 1986; Fisone et al., 1987; O’Donnell
et al., 1999). Accordingly, when galanin is injected directly into the ventral hippocampus
where there is higher GAL-R1 expression, learning and memory was impaired in the
Morris water task. Conversely, when galanin is injected into the dorsal hippocampus, no
learning deficits were detected (Ogren et al., 1999). GAL-R2 activation appears to
increase the levels of inositol phosphates and intracellular calcium in cell cultures,
leading to increased LTP and synaptic plasticity (Fathi et al., 1998; Kolakowski et al.,
1998; Wang et al., 1998; Wittau et al., 2000). Thus, GAL-R2’s appear to activate
phospholipase C and protein kinase C, initiating a signal transduction pathway which
promotes neurotransmission and facilitates learning and memory. Furthermore, activation
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of the GAL-R2 protects the hippocampus from neuronal damage, implicating this
receptor subtype in the trophic role galanin plays (Elliot-Hunt et al., 2007).
The third galanin receptor subtype (GAL-R3) appears to be similar to GAL-R1 in
functionality, coupling to the Gi protein, however the prevalence of GAL-R3 within the
CNS is much less extensive and considerably more studies are needed on this receptor
(Kolakowski et al., 1998; Smith et al., 1998). Thus, depending on which galanin receptor
is activated, the effect may be inhibitory or excitatory; a distinction necessary to make in
order to understand what is occurring in AD. In AD, the overexpression of galanin may
be inhibitory, further exacerbating cognitive deficits, or it may be neuroprotective,
attempting to save CBF neurons from any further damage.
AD patients exhibit characteristic memory loss and learning deficits, especially in
later stages of the disease. When galanin is centrally administered to rodents, it causes
learning and memory deficits, specifically deficits in the consolidation of memory
(Kinney et al., 2003). Because of this finding and others like it, it can be said that it is
possible that the overexpression of galanin seen in AD is contributing to the cognitive
impairments exhibited in the disease. The mechanism by which galanin may contribute to
the cognitive impairment has not been clarified, although many findings suggest it is
through interactions with the cholinergic system (Fisone et al., 1987; Chan-Palay, 1988;
Dutar et al., 1989; Mufson et al., 1993).
The loss of CBF neurons in AD is accompanied by an increase in the activity of
the surviving cholinergic neurons (McDonald & Crawley, 1997). Because of galanin’s
role as an inhibitory neuromodulator, this increase in cholinergic activity may increase
galaninergic activity, thus inhibiting the remaining cholinergic neurons (Fisone et al.,
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1987; Chan-Palay, 1988; Chan-Palay, 1990; Mufson et al., 1993; Bowser et al., 1997).
The inhibition of surviving cholinergic neurons may then lead to the learning and
memory problems characteristic of late-stage AD, because of the aforementioned
importance of acetylcholine in learning and attentional processes. This theory is
supported by findings that galanin expression progressively increases in the basal
forebrain in AD (Mufson et al., 2000). Galaninergic fibers form a dense plexus
surrounding surviving CBF neurons, reaching concentrations twice that of age-matched
controls (Beal et al., 1990). Although there is evidence of increased galaninergic activity
early in the disease progression (Perez et al., 2002), it appears that galanin
hyperinnervation of CBF neurons only occurs in the late stage of the disease (ChanPalay, 1988; Mufson et al., 1993; Bowser et al., 1997; Mufson et al., 2000; Counts et al.,
2006). These findings are consistent with the notion that galanin overexpression is
triggered by neuronal damage, suggesting galanin hyperinnervation of CBF neurons
represents a neuronal survival mechanism (Gabriel et al., 1995; Hartonian et al., 2002;
Shen et al., 2003).
In a recent study examining tissue from AD brains, it was found that CBF neurons
that are hyperinnervated by galanin show a significant increase in choline
acetyltransferase (ChAT) expression as compared to CBF neurons that have no GAL
hyperinnervation (Counts et al., 2008). The increase in ChAT due to galaninergic
hyperinnervation observed in this study suggests a neuroprotective role for galanin in
AD. In a study using saporin to produce a cholinergic-specific lesion in the basal
forebrain of rats, it was found that galanin immunoreactivity within and adjacent to the
lesion was significantly increased as compared to control animals, an effect that persisted
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long after the treatment (Hartonian et al., 2002). Thus, damage to cholinergic neurons
would appear to be sufficient to increase galanin expression long-term as a trophic
response to the damage. However, in Down’s syndrome which also produces extensive
CBF degeneration, galanin does not hyperinnervate surviving cholinergic neurons
(Mufson et al., 1993; Sendera et al., 2000). These findings suggest that CBF neuron loss
alone is insufficient to trigger the galanin plasticity response seen in AD. Therefore, it
may be that galanin is overexpressed in AD due to other factors such as the Aβ plaques or
the NFT or the excitotoxicity. Whether galanin is protecting or inhibiting CBF neurons in
AD is still unknown, but it is clear the neuropeptide needs to be studied further in order to
fully understand its role in this neurodegenerative disease.

Hypothesis and Implications
Many theories have been proposed to explain the neurodegeneration which occurs
in AD, but none so far have been able to account for the massive neuronal loss and
progressive cognitive decline seen in the disease. Galanin may provide a critical link in
the causal chain of AD, and thus the current study has potential implications for future
Alzheimer’s research. The effects of the co-administration of donepezil and galanin
should provide valuable insight into AD pathology and further supplement the literature
related to ACh and galanin.
In a series of experiments we attempted to determine if galanin exerts its effects
on learning and memory via modulation of cholinergic tone in an intact nervous system,
as well as to examine its effects in an animal model of AD when co-administered with a
drug that is used to treat the disorder. In experiment 1, we investigated the effects of
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galanin when co-administered with donepezil in a spatial learning task, the Morris water
maze, in an effort to clarify the mechanism by which galanin impairs learning and
memory. If the galanin-induced deficit is altered by the addition of donepezil, it is likely
galanin is impairing learning and memory in part via inhibition of cholinergic
mechanisms. However, if donepezil has no effect on the galanin-induced deficit, then the
deficit is likely unrelated to cholinergic alterations. Recent data from our lab indicate a
drastic reduction in CREB (cAMP-response element binding protein) phosphorylation, a
critical event for the induction of LTP and learning and memory (Comb et al., 1986;
Dash et al., 1990; Bartsch et al., 1998), following galanin administration (Kinney et al.,
2009). In addition, these changes have been linked to the learning impairments observed
following exogenous galanin administration (Kinney et al., 2003). Therefore, we
hypothesized that donepezil would be unable to rescue the galanin-induced deficit, and
that galanin’s inhibition of CREB phosphorylation may be principally responsible for the
learning deficit.
There is a paucity of evidence on the role galanin may play following a
cholinergic lesion with regard to both the survivability of cholinergic neurons and
learning and memory. In experiment 2, we examined the effects of donepezil and galanin
following the central administration of a cholinergic-specific neurotoxin, AF64A,
designed to mimic an early or even preclinical stage of AD. While previous
investigations have been carried out on either the effectiveness of AChEIs following a
cholinergic lesion or the potential role of galanin in AD, there have been no studies
examining both galanin and AChEIs in a model consistent with AD. Whether or not
galanin functions in a neuroprotective capacity following a cholinergic lesion as well as
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how it affects learning following damage are key concepts that have yet to be addressed.
In addition, we sought to determine what effect the co-administration of donepezil and
galanin would have in a compromised cholinergic system. We hypothesized that
donepezil would rescue any lesion-induced learning and memory deficits by increasing
the amount of available ACh and restoring the functioning of the cholinergic system to a
physiologically normative level. We further hypothesized that although galanin may not
rescue the lesion-induced impairment, it may potentially reduce the degree of cell loss in
these animals if it does act as a trophic factor in vivo. Finally, we expected that coadministration of donepezil and galanin would lead to a partial rescue of the learning and
memory deficits caused by AF64A. However, we hypothesized that the inhibitory effects
of galanin would not allow a complete reversal of the lesion-induced deficits.
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CHAPTER 3
MATERIALS AND METHODS
Subjects
Ninety adult male Sprague-Dawley rats (forty for Experiment 1 and fifty for
Experiment 2) approximately three months of age and weighing between 250 and 350 g
were used. Rats were maintained in a temperature and humidity (22 ± 1°C) controlled
facility, with food and water available ad libitum, on a 12:12 light/dark cycle, lights on at
7:00 a.m. Animals were housed in pairs until the time of the surgery, after which they
were individually housed. All procedures were approved by the University of Nevada,
Las Vegas Institutional Animal Care and Use Committee and carried out in accordance
with NIH guidelines for the appropriate care and use of animals.

Surgery
Surgeries were performed as described previously by Kinney et al. (2003).
Briefly, all animals underwent stereotaxic surgery under aseptic conditions and ketamine
(66 mg/kg; Henry Schein Inc, Sparks, NV) and dexmedetomidine (0.2 mg/kg; Henry
Schein Inc, Sparks, NV) anesthesia. A guide cannula 1.4 cm in length, 24-gauge stainless
steel hypodermic tubing (Plastics One, Roanoke, VA) was implanted into the right lateral
ventricle at coordinates 0.5 mm posterior, 1.2 mm lateral to bregma, and 3.5 mm ventral
to the surface of the skull (Paxinos & Watson, 1986). The cannula was secured to the
skull using stainless steel screws and dental acrylic. A 31-gauge stylet was inserted to
close the guide cannula. Rats were administered an analgesic (Buprenorphine, 0.05
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mg/kg; Henry Schein Inc, Sparks, NV) immediately following surgery as well for two
days post-surgery to minimize post-operative pain.

Drug Treatments
Rat galanin 1-29 (Bachem Americas, Inc. Torrance, CA) was dissolved in 0.9%
physiological saline vehicle at a concentration of 3 nmol/3 µl. Donepezil hydrochloride
(Tecoland Corporation, Edison, NJ) was dissolved in 0.9% physiological saline to a
concentration of 0.3 mg/kg. AF64A was dissolved in NaOh to a concentration of 0.34
mg/ml and pH was adjusted to between 7.0 and 7.4. The toxin was administered into the
right lateral ventricle, 2 µl total, over the course of one minute with the injector being left
in for an additional minute to ensure complete distribution of the solution. Subjects were
randomly assigned to different treatment groups, each of which consisted of a daily pretreatment administered intra-peritoneally (i.p. 1 ml/kg) and a daily treatment administered
intracerebroventricularly (i.c.v. 3 µl infused). The pre-treatment was given 20 minutes
prior to behavioral testing and the treatment was given 5 minutes before testing. Saline
was administered as a control for i.p. pre-treatments and artificial cerebrospinal fluid
(ACSF) was administered as a control for i.c.v. treatments.
For the first experiment, a control group received a saline pre-treatment and a
treatment of ACSF. The remaining three groups received daily administrations of either a
donepezil pre-treatment and a treatment of ACSF, a saline pre-treatment and a treatment
of galanin, or a pre-treatment of donepezil and a treatment of galanin. In Experiment 2,
four of the five groups received a one-time infusion of AF64A an average of four days
before behavioral testing began. A control group received a sham-lesion, using ACSF
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instead of the toxin, and a pre-treatment of saline followed by treatment with ACSF. The
remaining toxin-infused groups received daily administrations of either a pre-treatment of
saline and a treatment of ACSF, pre-treatment of donepezil and a treatment of ACSF,
pre-treatment of saline and a treatment of galanin, or pre-treatment of donepezil and a
treatment of galanin. Table 1 outlines the drug administrations for each group in
experiments 1 and 2.

Table 1
Experiment 1
Pre-treatment

Treatment

Saline

ACSF

Donepezil

ACSF

Saline

Galanin

Donepezil

Galanin

Experiment 2
Before Testing

Pre-treatment

Treatment

Sham lesion

Saline

ACSF

Lesion

Saline

ACSF

Lesion

Donepezil

ACSF

Lesion

Saline

Galanin

Lesion

Donepezil

Galanin
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Morris Water Task
The Morris water task was conducted in a circular tank, 1.8 m in diameter
and 76 cm in height, made of white polyethylene 4.7 mm in thickness (San Diego
Instruments, San Diego, CA). Tap water, 48 cm deep, was maintained at a temperature of
25°C and made opaque by the addition of white non-toxic paint (Fresco Tempera Paint,
Rich Art Color Company, Northvale, NJ), and changed every other day. The escape
platform, a square platform 10 cm in diameter made of clear plastic, was placed in the
center of one of the four quadrants (target quadrant), 30 cm from the inside wall of the
maze and 1.5 cm below the surface of the water. For visible platform training, a large
black and white cover was attached to the top of the platform and protruded 2 cm above
the water.
Trials were recorded and captured using a video tracking system (Smart, San
Diego Instruments, San Diego, CA) recorded from a Sony Handycam camera connected
to a Cobalt Instruments computer. Data collected for each trial consisted of a track of the
animal which included the latency to locate the platform, speed of swimming, and
thigmotaxis. On the probe trial the tracking system also recorded the amount of time
subjects spent in each of the four quadrants of the maze, as well as the number of times
the animal’s path crossed over the previous platform location and its analogous location
in each quadrant.

Behavioral Testing
Animals received AF64A toxin infusions an average of four days before testing
began in order to alter the cholinergic system consistent with early stages of AD. Daily
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injections of donepezil or saline were administered 20 minutes prior to start of testing,
while galanin or ACSF was centrally infused 5 minutes before testing began. Subjects
were then taken individually from the colony room to a dedicated testing room containing
the water maze, a computer desk, a table with the heating cage, and large geometric
shapes positioned on each of the four walls, all serving as distal spatial cues. The rat was
placed into the maze at one of three randomized locations, in the center of a quadrant that
did not contain the escape platform (non-target quadrant). The rat was allowed to swim in
the maze until it reached the hidden platform and placed its forepaws on the platform. If
after 60 seconds the animal did not locate the hidden platform, it was guided to the
platform by the experimenter. The rat was given 20 seconds on the platform to orient to
distal spatial cues and was then placed under a heat lamp for a total of 30 seconds
between trials. Three additional trials were conducted in an identical fashion, for a total
of four training trials per day. Following the fourth trial, the animal was dried and then
returned to its home cage. The training trials for the hidden platform were conducted until
control subjects reached a latency criterion of less than 20 seconds for experiment 1 and
less than 13 seconds for experiment 2. A more stringent criterion was set for experiment
2 in order to ensure lesion animals had sufficient opportunity to learn the task. A probe
trial was conducted five hours following achievement of this criterion. For probe trials,
the rat was placed in the maze in the same fashion as during training, but the escape
platform was absent. The single probe trial was 60 seconds in duration, after which the
rat was dried and returned to its home cage.
The day after completion of the probe trial, a visible platform training protocol
was used. A visible platform that extends above the surface of the water (intra-maze cue)
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was placed into the maze instead of the hidden platform. Five trials were conducted for
each animal in the same fashion as during the hidden platform training, with the
exception that the platform location was changed on each trial. Visible platform training
was conducted in order to detect any deficits in visual ability and motor function. Thirty
minutes following completion of the last visible training trial, animals were humanely
euthanized.

Tissue Collection
Animals were humanely euthanized via carbon dioxide asphyxiation and half
were transcardially perfused while the other half were immediately decapitated for rapid
removal of the brain. Transcardiac perfusions involved perfusing saline through the
vascular system via the left ventricle followed by perfusion of 8% paraformaldehyde to
fix the tissue. Brains were then removed and placed in 8% paraformaldehyde at 4° C for
48 hours followed by 24 hours in a 30% sucrose solution in PBS (phosphate-buffered
saline). Finally, brains were placed in 5% sucrose in PBS until immunohistochemistry
experiments. For rats that did not receive transcardiac perfusions, brains were quickly
removed and cortex, hippocampi, and cerebellum were dissected out and flash frozen in
dry ice. The dissected tissue was stored at -80° C until western blotting experiments.

SDS-PAGE (Western Blots)
A total of twenty-four animals were randomly selected for the SDS-PAGE
experiments which were only conducted with subjects from experiment 2. Tissue was
homogenized in a non-denaturing lysis buffer consisting of 1X RIPA buffer (Cell
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Signaling; 20 mM Tris-HCL pH 7.5, 150 mM NaCL, 1 mM Na2 EDTA, 1 mM EGTA,
1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM βglycerophosphate, 1 mM Na3VO4, and 1 µg/ml leupeptin), 1 mM DTT, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 20 µg/ml aprotinin and 0.1% sodium dodecyl
sulfate (SDS). Lysates were centrifuged at 15,000 x g for 15 minutes at 4°C, the
supernatant was collected, and a protein assay to determine concentration was performed
using the biciconinic acid method (BCA, Pierce, Rockford, IL). Samples (20 µg) were
separated on 10% SDS-PAGE gels according to the method of Laemmli (1970). Proteins
were then electro-transferred to nitropure 45 micron nitrocellulose membranes which
were blocked in 5% milk in Tris-buffered saline 0.05% Tween (TBST) and sodium azide
overnight.
Individual membranes were incubated with rabbit anti-VAChT (vesicular ACh
transporter) antibody (1:750; Sigma-Aldrich, St. Louis, MO) or rabbit anti-β-actin
antibody as control (1:1000; Sigma-Aldrich, St. Louis, MO) in TBST-5% milk plus
sodium azide for 2 hours at room temperature. Detection of specific binding was
performed by incubation with HRP-conjugated secondary antibodies (1:5000, Vector) for
1 hour at room temperature. Specific signals were detected with Super Signal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL) and images were then scanned for
densitometry, using BioSpectrum Imaging System (UVP, Upland, CA) and average
intensity was obtained for each sample using ImageJ software (National Institutes of
Health).
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Immunohistochemistry
Twenty-three animals, all from experiment 2, were dedicated to
immunohistochemistry experiments. Whole brains were sectioned at a thickness of 20µm
on a cryostat and sections were stored at 4° C in PBS until the immunohistochemistry
experiments. In order to verify correct cannula placement, sections were examined to see
if cannulae terminated in the lateral ventricles. Animals whose cannulae did not terminate
in the lateral ventricle were removed from the analyses. Sections were placed in plastic
wells and remained free floating until the completion of the immunohistochemistry
procedure. Sections were initially blocked for 45 minutes in a blocking solution
containing 5% normal goat serum (NGS), 0.05% Tween, and PBS. Sections were then
incubated overnight at room temperature in primary antibody solution containing 5%
NGS, 0.3% Tween, 0.05% sodium azide, and primary polyclonal antibody raised in
rabbit directed against the VAChT (1:750 dilution). All wells were then rinsed five times
for five minutes each in an excess of wash solution (PBS, 0.2% NGS, and 0.05% Tween)
with gentle rotation. Following the washes, sections underwent a procedure for labeling
with 3, 3’ diaminobenzidine (DAB). Sections were incubated for 45 minutes in a
biotinylated secondary antibody solution containing 5% NGS, PBS, and biotinylated
secondary antibody (1:500 dilution; Elite Vectastain ABC kit, Burlingame, CA).
Following five washes, sections were washed for 15 minutes in a hydrogen peroxide
solution (3% hydrogen peroxide, 1% sodium azide, and wash solution) to eliminate nonspecific binding and then washed three more times. Sections were then incubated for 45
minutes with ABC reaction in order to amplify the signal (Elite Vectastain ABC kit,
Burlingame, CA) followed by another five washes. Finally, syringe-filtered DAB was
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placed into the wells while the sections were free-floating for four minutes and then
washed away using wash solution. Sections were then mounted onto slides for imaging
under the microscope.

Cell Counting
To determine the extent of cholinergic neuron loss in subjects from all groups
administered the AF64A or sham lesion, slides were examined at an objective of 10X or
20X using a Zeiss Axioskop II Plus microscope (Carl Zeiss MicroImaging, Inc,
Thornwood, NY). Cell counts of VAChT-positive neurons within the basal forebrain and
hippocampus were performed in a consistent manner across sections and groups. A
minimum of six sections per animal with three to four animals per group was utilized to
determine relative cholinergic abundance expressed as a percent of the sham controls.

Statistical Analysis
Hidden platform training data were analyzed using the SPSS statistical software
package by a repeated measures analysis of variance (ANOVA). Visible platform training
and probe trial data were analyzed by one-way ANOVA. Western Blot densitometry and
cell count data were also analyzed by one-way ANOVA. Tukey post-hoc comparisons of
treatment groups were performed following a significant ANOVA.
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CHAPTER 4
RESULTS
Experiment 1
Morris Water Maze
An analysis of each group’s latency to reach the hidden platform in the
Morris water maze revealed no significant differences among the groups (F3,124 = 0.208,
p=.891; see figure 1A). Similarly, there were no significant differences among the groups
in latency to find the visible platform (F3,131 = 1.197, p=0.314; see figure 1A). Speed of
swimming was analyzed to investigate any differences in motoric ability among the
groups. No significant differences were found among the groups with regard to swim
speed during hidden training (F3,124 = 0.975, p=.407; see figure 1B) or visible training
(F3,131 = 1.731, p=0.164; see figure 1B). Thigmotaxis, a measurement of how much time
subjects spent around the outer perimeter of the maze, is typically used as a measure of
anxiety. During hidden platform training, no significant differences were observed among
the groups in thigmotaxis (F3,124 = 0.173, p=.915; see figure 1C). However, during visible
platform training, significant differences were observed in thigmotaxis (F3,131 = 3.114,
p<.05; Tukey post-hocs revealed that the donepezil-galanin group had significantly
higher thigmotaxis than the saline-ACSF group, p<.05; see figure 1C).
Following hidden platform training, the platform was removed and a probe trial
was conducted to assess spatial learning (see figure 1D). A lack of a significant probe
trial indicates a group did not learn the spatial location of the platform. Subjects in the
saline-ACSF group spent significantly more time in the target quadrant versus each of the
three non-target quadrants indicating a selective preference for the target location (F3,32 =
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27.912, p<.01; Tukey post-hoc comparisons of target quadrant versus all non-target
quadrants, p<.01). Rats administered donepezil and ACSF also displayed a significant
search (F3,24 = 11.834, p<.01; Tukey post-hoc comparisons of target versus all non-target
quadrants, p<.01). Animals that received saline and galanin did not show a selective
search as not all non-target quadrants were significant versus the target (F3,28 = 5.759,
p<.01; Tukey post-hocs revealed target was only significant versus quadrant 1, p<.01,
and non-significant versus quadrants 2 and 3, p>.05) which is consistent with previous
studies with galanin. Interestingly, in the group given donepezil and galanin, rats did not
show a preference for the target quadrant (F3,28 = 2.350, p=.094).

Experiment 2
Morris Water Maze
Administration of the cholinergic neurotoxin alone or in combination with galanin
and/or donepezil did not affect the animals’ latencies to find the hidden platform in the
Morris water maze as is evidenced by the observation of no significant differences among
the groups (F4,167 = 0.555, p=.696; see figure 2A). Interestingly, during visible platform
training there was a significant difference in latency to reach the platform (F4,157 = 2.769,
p<.05; Tukey post-hocs revealed that the lesion plus donepezil and galanin led to a
significantly higher latency to reach the visible platform as compared to sham controls,
p<.05; see figure 2A). No swim speed differences were observed in either hidden training
(F4,167 = 2.181, p=.073) or visible platform training (F4,157 = 0.521, p=.721) among the
groups (see figure 2B). When thigmotaxis was analyzed, a significant difference was
found among the groups during hidden platform training (F4,167 = 2.760, p<.05; Tukey
post-hocs showed the lesion plus donepezil and galanin produced significantly higher
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Figure 1. Water maze performance in experiment 1 following donepezil and/or galanin
administration. (A) Latency for hidden and visible platform training. No significant
differences were found among treatments during either condition (p>.05). (B) No swim
speed differences were detected among groups in either hidden or visible platform
training (p>.05). (C) An examination of time spent around the outer perimeter of the
maze revealed a significant difference in thigmotaxis during visible platform training in
the donepezil-galanin group (p<.05) versus controls but no differences during hidden
training. (D) Probe trial data show that only saline controls (p<.01) and donepeziladministered animals (p<.01) spent significantly more time in the target quadrant versus
each non-target quadrant indicative of a selective search. Groups administered galanin or
donepezil and galanin did not display a selective search (p>.05).
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thigmotaxis as compared to the sham controls, p<.05; see figure 2C). Similarly, during
visible platform training significant differences were found among treatments (F4,157 =
3.603, p<.01; Tukey post-hocs showed no significant differences compared to sham
controls; however, the lesion plus donepezil and galanin produced significantly higher
thigmotaxis as compared to the lesion group, the lesion plus donepezil, and the lesion
plus galanin, ps<.05; see figure 2C).
Figure 2D depicts probe trial performance among the groups administered either
AF64A or a sham lesion. Sham controls demonstrated a selective search as is evidenced
by their significant probe trial (F3,32 = 59.444, p<.01; Tukey post-hoc comparisons of
target versus all non-target quadrants, p<.01). Animals administered the lesion alone also
showed a selective probe trial (F3,32 = 13.231, p<.01; Tukey post-hoc comparisons of
target versus all non-target quadrants, p<.01). Surprisingly, rats infused with galanin
following the lesion demonstrated a significant search as well (F3,28 = 38.027, p<.01;
Tukey post-hoc comparisons of target versus all non-target quadrants, p<.01). Equally
surprising was that the lesion plus donepezil and galanin group also exhibited a
significant search on the probe trial (F3,32 = 44.361, p<.01; Tukey post-hoc comparisons
of target versus non-target quadrants, p<.01). Interestingly, the group administered
donepezil and ACSF following the lesion did not display a selective search during the
probe trial (F3,28 = 5.345, p<.01; Tukey post-hocs revealed target was only significant
versus quadrant 3, p<.01, and non-significant versus quadrants 1 and 2, p>.05).
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Figure 2. Water maze performance in experiment 2 following a lesion and combinations
of donepezil and galanin. (A) No differences were observed during hidden platform
training although the lesion plus donepezil and galanin group displayed a significantly
increased latency to find the visible platform (p<.05) versus sham controls. (B) No
significant differences in swim speed were observed in either hidden or visible platform
training (p>.05). (C) A significantly increased thigmotaxis was observed in the lesion
plus donepezil and galanin group during hidden platform training (p<.05) versus sham
controls and during visible platform training (p<.05) versus lesion, lesion plus donepezil,
and lesion plus galanin groups but not sham controls. (D) Probe trial data indicate that
sham controls (p<.01), lesion (p<.01), lesion plus galanin (p<.01), and lesion plus
donepezil and galanin (p<.01) groups all spent significantly more time in the target
quadrant versus each non-target quadrant. However, animals administered the lesion plus
donepezil did not display a selective search indicating they did not learn the location of
the platform (analysis of target versus non-target quadrants, p>.05).
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Western Blotting
Western Blots were analyzed for image intensity and statistics were performed to
examine differences among treatments. Representative blots of frontal cortex are shown
in figure 3A. While there are indications of differences among groups, no significant
differences among treatments were observed in protein levels of VAChT in the cortex
(F4,31 = 1.637, p=.190; see figure 3A). A representative blot for the hippocampus is shown
in figure 3B. Similar to cortex samples, although differences exist among treatments, no
significant differences were found among groups in the hippocampus (F4,35 = 1.435,
p=.243; see figure 3B).
Cell Counts
Cell counts performed under light microscopy of DAB-stained tissue were done
in the left and right basal forebrain region and left and right hippocampi to assess the
number of cholinergic neurons. A significant difference was observed among the groups
in the total number of VAChT-positive cells counted in the left and right basal forebrain
(F4,203 = 3.464, p<.01; Tukey post-hocs revealed that the lesion plus galanin group had
significantly fewer cholinergic-positive neurons in the basal forebrain as compared to
sham controls, p<.05; see figure 4D). The lesion alone group displayed a non-significant
trend toward a loss of cholinergic cells as compared to sham controls, however it did not
reach significance, p=.095. Representative images of basal forebrain for sham controls,
lesion, and lesion plus galanin groups are depicted in figure 4 (A, B, and C, respectively).
Images for lesion plus donepezil and lesion plus donepezil and galanin groups are not
shown due to the lack of significant differences between these groups and controls. Cell
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counts performed in the hippocampus revealed no significant differences among
treatments (F4,74 = 0.613, p=.655; data not shown).
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Figure 3. Western Blot analyses. (A) Representative blots of samples from the frontal
cortex along with the relative VAChT protein levels in each group compared to sham
controls. Analyses of Western Blot densitometry revealed no significant differences
among the groups (p>.05). (B) Representative blots of hippocampal samples along with
the relative protein levels of VAChT compared to sham controls. No significant
differences were observed among the groups (p>.05). S: sham controls; L: lesion; L + D:
lesion + donepezil; L + G: lesion + galanin; L + D + G: lesion + donepezil + galanin.
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Figure 4. Immunohistochemical cell counts within DAB-stained basal forebrain sections.
(A) Representative image of a sham control brain. (B) Representative image of a lesion
animal. (C) Representative image of a rat from the lesion plus galanin group. (D) An
analysis of cell counts performed within the basal forebrain revealed that the lesion plus
galanin group had significantly fewer VAChT-positive cells than sham controls (p<.01).
All images were obtained at a 10X magnification.
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CHAPTER 5
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS
Discussion of Results
In the above studies we investigated the interaction of galanin and the
cholinergic system with particular relevance to AD. Here we present the first behavioral
evidence that the galanin-induced learning and memory impairment is likely not related
to galanin modulating cholinergic signaling. Experiment 1 demonstrated that the
previously observed deficit in spatial learning and memory due to galanin was not
rescued or even modified by the administration of the AChE inhibitor donepezil. Several
previous investigations have made a case for the impairments produced by galanin being
driven by altering cholinergic tone (Melander et al., 1985; Fisone et al., 1987; Dutar et
al., 1989; Mufson et al., 1998). This connection has also been used extensively to support
the models of galanin overexpression in AD.

If the galanin-induced alteration of

cholinergic signaling were in part responsible for its learning and memory deficits, the
increase in cholinergic tone produced by donepezil should have altered and/or rescued the
galanin-induced impairment.
In a recent study investigating the mechanisms responsible for the galanin
learning deficit, it was found that galanin significantly reduced CREB phosphorylation
(Kinney et al., 2009). Further, another investigation found that the administration of
forskolin (an AC activator) was able to rescue the galanin-induced deficit (Kinney et. al.
2003), providing further support that the spatial learning and memory deficits due to
galanin may be mediated by its inhibition of AC activity and downstream
phosphorylation of CREB. Taken together, these data suggest that the investigation of
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galanin deficits should focus more specifically on the intracellular signaling cascades
modulated by galanin. However, the possibility still remains that the cholinergic cell loss
and overexpression of galanin observed in AD result in a completely different scenario.
In order to examine the relationship between cholinergic cell loss similar to what
is observed in AD and increased galanin levels, a cholinergic neurotoxin was centrally
administered in experiment 2. When the interactions of donepezil and galanin were
examined in a compromised cholinergic system, a completely different behavioral profile
emerged. Most notably, the galanin-induced deficit, which has been well characterized in
tasks of spatial learning and memory, was absent following the cholinergic lesion. In
addition, donepezil administration following the lesion produced a deficit in the probe
trial indicating these animals did not learn the spatial location of the platform. This result
was somewhat surprising as the majority of the literature suggests that increasing
cholinergic tone is beneficial to an organism. Importantly, co-administration of donepezil
and galanin following the cholinergic lesion did not produce a learning and memory
impairment even though higher thigmotaxis was seen throughout training in this group.
Further, a deficit in latency to reach the visible platform was observed in these animals
which can largely be accounted for by the increase in thigmotaxis observed during visible
training. Because this group did not show any impairment in hidden platform training or
the probe trial, this visible platform deficit is not likely due to any visuomotor
impairments. Interestingly, animals co-administered donepezil and galanin in experiment
1 also displayed increased thigmotaxis during visible platform training suggesting an
anxiety phenotype may be present following co-administration of these compounds.
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Future studies may be able to clarify any anxiogenic effects related to the interaction of
galanin and donepezil.
In the group administered a cholinergic lesion followed by saline and ACSF, no
spatial learning and memory deficit was detected. Although this result was also
unexpected, the data on spatial learning and memory following a cholinergic lesion are
fairly inconsistent (Walsh et al., 1984; Lamberty et al., 1992; Nakamura et al., 1992;
Opello et al., 1993; Dornan et al., 1996; Bizon et al., 2003; Frick et al., 2004; Dashniani
et al., 2009). Whether or not a learning deficit is observed is likely tied to the extent of
the cholinergic lesion and the particular neurotoxin employed. The unilateral cholinergic
lesion administered in the current study was selected to induce mild damage to the basal
forebrain, in an effort to mimic early or even preclinical AD. Thus, because our
cholinergic insult was relatively small, the spatial learning task utilized may not have
been sensitive enough to detect any behavioral changes due to the lesion. However, it is
clear the lesion itself did have a physiological and behavioral impact as the effects of
galanin and donepezil become radically different following the lesion versus in a normal,
non-lesioned animal. Further, although not significant, there was a marked reduction in
the amount of cholinergic-positive cells in the basal forebrain region of lesioned animals.
The results from the Western Blot and immunohistochemistry (IHC) experiments
are a little less clear. Although disagreements exist on the accuracy of quantitative IHC
techniques, the IHC experiments disclose useful and interesting information regarding
neurobiological changes. Based on our data, there is a significant reduction in the amount
of VAChT-positive cells in the basal forebrain region in animals administered the lesion
plus galanin as compared to sham controls. This finding is contrary to what we expected
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given the trophic effects that have been observed following galanin administration in
vitro (Zini et al., 1993; Holmes et al., 2000; O’Meara et al., 2000; Mahoney et al., 2003;
Elliot-Hunt et al., 2007). Further, because galanin administration following the lesion did
not produce a learning and memory deficit in the water maze, this significant reduction in
cholinergic-positive cells is even more surprising. The possibility exists that although
galanin may not exhibit any neuroprotective qualities in vivo, its effects in a
compromised cholinergic system are different than in a normal, non-lesioned animal.
More data related to the in vivo effects of galanin in animal models relevant to the
specific disease state may be necessary to clarify this galanin-induced change.
There is also a non-significant trend (p=.095) towards a reduction in cholinergic
cells in lesioned animals. Although this reduction did not reach significance in this group,
it is clear the lesion did alter the amount of VAChT-positive cells in the basal forebrain.
Interestingly, in the lesion plus donepezil and lesion plus donepezil and galanin groups,
there is very little change in the amount of cholinergic neurons as compared to sham
controls. Whether this lack of a reduction in cholinergic cells in these groups reflects any
neuroprotective properties of donepezil is difficult to determine with the data at hand.
However, previous studies have discovered possible neuroprotective effects of donepezil
(Takada-Takatori et al., 2006; Akasofu et al., 2008), raising the possibility that daily
donepezil administration may have negated the effects of the lesion in the current study.
Interestingly, impairments in water maze learning were observed in the group
administered donepezil following the lesion. These results suggest compensatory changes
following the lesion in combination with donepezil administration may have disrupted
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spatial memory. Further possibilities regarding the behavioral deficit in this group are
outlined below.
An analysis of the densitometry of the Western blots revealed no significant
differences among the groups in either the cortex or the hippocampus. Interestingly
however, the trends in the VAChT protein levels in the cortex seem to mirror the group
differences observed following the IHC cell counts. The consistency observed between
procedures in the differences among groups reinforces the validity of the findings.
Further, although there is a large amount of variability within each group, clear trends are
observable in the hippocampus as well. It is interesting to note that these trends tend to be
opposed to the data from the Western blot cortex samples and the IHC basal forebrain
cell counts. Spatial learning and memory in the Morris water maze is a hippocampallydependent task. Therefore, the shift in VAChT protein levels in the hippocampus in some
of these groups could potentially account for why a deficit is observed in the lesion plus
donepezil group while none is found in the lesion plus galanin group. Specifically, the
Western data indicate that the lesion plus donepezil group has lower levels of VAChT
protein in the hippocampus than the lesion and lesion plus galanin groups. This difference
may play a role in the lesion plus donepezil group deficit, as further outlined below. The
large variability observed within each group precludes the discovery of any significant
differences among these groups, and a replication of these findings may be necessary
before any definitive conclusions can be reached regarding the neurobiological effects of
donepezil and/or galanin following a lesion.
The data from the above experiments indicate an interesting shift in the effects of
galanin as well as the interaction of donepezil and galanin. In experiment 1, donepezil
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alone did not alter performance while galanin impaired spatial learning and memory
consistent with previous investigations. Interestingly, the galanin deficit was still present
when donepezil was co-administered indicating the galanin learning impairment is likely
not related to the suppression of cholinergic signaling. However, in the presence of a
cholinergic lesion these effects were inverted. Following perturbation of the cholinergic
system as in AD, the same dose of donepezil produced a spatial learning impairment
while the same concentration of galanin (from the same batch) or co-administration of
galanin and donepezil did not lead to a learning impairment. Even more compelling is
that the cholinergic lesion alone was insufficient to impair learning and memory in the
water maze. These data suggest that there are differential effects of both galanin and
donepezil depending on the level of cholinergic tone. Further, it is also interesting to note
that while the galanin deficit does not appear to be tied directly to the modulation of
ACh, following the reduction of cholinergic tone as in AD, galanin does not produce an
impairment. In addition, although administration of donepezil following the lesion
impaired water maze performance, when galanin was co-administered with donepezil,
this donepezil-induced deficit vanished. These data suggest that galanin may have a
beneficial role in a compromised cholinergic system similar to what is observed in AD.
These findings also support a more detailed investigation of galanin activity in specific
disease state models as opposed to previous investigations of exogenous galanin
administered to normal subjects.
The role of galanin in AD is currently unknown with many investigators
suggesting it may be exacerbating cognitive symptoms while others support a potential
trophic role for galanin in the disorder. Interestingly, galanin has been shown to protect
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neurons from the toxic effects of Aβ (Ding et al., 2006; Cheng & Yu, 2010; Cui et al.,
2010) and has also recently been demonstrated to rescue Aβ-induced learning and
memory deficits in the Morris water maze (Cheng & Yu, 2010). These studies suggest the
overexpression of galanin may serve a protective role in AD in an attempt to counteract
the neurotoxic effects of Aβ. In the current study when cholinergic functioning was
altered, galanin may also display protective properties similar to what is seen following
Aβ infusion. However, the histological data did not reveal any neuroprotective qualities
of galanin, indicating the lack of a behavioral deficit may be unrelated to galanin’s
trophic properties.
The cholinergic lesion also altered the behavioral outcome of donepezil
administration, producing a deficit where none was observed without the lesion. This
finding suggests neurological changes due to the lesion, perhaps compensatory in nature,
followed by the inhibition of AChE may have created a scenario where the increase in
cholinergic tone impaired spatial learning. In fact, there are reports that also demonstrate
spatial learning deficits due to increasing cholinergic tone (Bunce et al., 2004; Elvander
et al., 2004; Sabolek et al., 2005), particularly in the retrieval of previously learned
information (Rogers & Kesner, 2004). This retrieval deficit is especially relevant in our
study considering donepezil administration following the cholinergic lesion impaired
probe trial performance in the Morris water maze. However, further studies are necessary
to confirm and elucidate the mechanisms driving this donepezil-induced change. In
addition, no deficit was observed following co-administration of donepezil and galanin in
rats with a compromised cholinergic system, suggesting whatever effect galanin has
following a lesion is sufficient to rescue the donepezil-induced deficit. It is possible that
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the increase in cholinergic tone caused by donepezil was reduced by galanin
administration (Fisone et al., 1987; Dutar et al., 1989; Palazzi et al., 1991), which
restored ACh levels to a level consistent with other groups and eliminated the donepezilinduced deficit. Clearly, the interactions between galanin and the cholinergic system
become more complex following a cholinergic lesion mimicking early AD and more data
may be required before any definitive interpretations can be made.
Regardless of whether or not galanin plays a neuroprotective role in AD, based on
the findings from experiment 1, the behavioral deficits attributed to galanin are more
likely due to its inhibition of CREB phosphorylation (Kinney et al., 2009) and not tied to
suppression of cholinergic signaling. Further, it may be necessary to readdress the
behavioral consequences of galanin’s modulation of cholinergic functioning, especially in
early or preclinical AD when ACh levels begin to fall and cognitive deficits begin to
arise. A potentially more relevant approach to galanin in AD may be to address the
mechanisms responsible for its overexpression in AD.

This approach may provide

valuable data regarding the mechanisms involved in the pathology of AD. For example,
several groups have argued that calcium alterations may be tied to both the
neurofibrillary tangles and Aβ plaques observed in AD (McKee et al., 1990; Hardy &
Higgins, 1992; Mattson et al., 1992; Murray et al., 1992; Querfurth & Selkoe, 1994;
Green & Laferla, 2008; Lopez et al., 2008; Vale et al., 2010). As the transcriptional
regulation of galanin is on a calcium-dependent switch, specifically a CREB-dependent
transcription factor (Zachariou et al., 2001), the overexpression of galanin may be tied to
other pathological findings in AD. Changes in calcium levels consistently observed in
AD (Peterson et al., 1985; Landfield et al., 1989; Thibault & Landfield, 1996; Raza et al.,
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2007; Thibault et al., 2007; Bezprozvanny and Mattson, 2008; Bojarski et al., 2008)
could potentially lead to increased CREB activation and an upregulation of galanin. In
addition, as galanin has demonstrated neuroprotection against calcium-induced damage
(Palazzi et al., 1991; Mazarati et al., 2000; Arabadzisz et al., 2005; Mazarati et al., 2006;
Endoh et al., 2008), these changes in calcium levels alone could lead to the
overexpression of galanin in AD.
The potential upregulation of galanin following calcium dysegulation raises the
possibility of utilizing galanin as a marker in animal models and perhaps AD as well. If
the overexpression of galanin observed in AD and animal models of AD (Baraka &
ElGhotny, 2010) is due to changes in calcium levels, then measuring levels of galanin
may prove fruitful in the detection of AD in vivo. The development of galanin receptor
ligands for clinical use has proven challenging. Therefore, investigations of galanin in
AD may be better served by examining levels of galanin as a marker for cell damage or
cell loss due to calcium alterations.
The role of galanin in inhibiting the evoked release of classical neurotransmitters
and preventing neuronal hyperactivity has been well documented (Dutar et al., 1989;
Pieribone et al., 1995; Kinney et al., 1998; Xu et al., 1998). However, galanin’s inhibition
of CREB phosphorylation provides a possible alternative explanation for its potential
neuroprotective properties in a damaged nervous system. By inhibiting AC and
downstream phosphorylation of CREB, galanin may be conserving vital resources by
halting the activation of several transcription factors. This reduction in transcription may
allow a struggling nervous system to allocate resources where necessary without
expending unwanted energy, which could be critical in a neurodegenerative disorder such
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as AD. In the current study, galanin did not produce a spatial learning and memory
impairment when administered to an animal with a compromised cholinergic system.
This finding is unique as previous investigations with several learning and memory tasks
have typically demonstrated learning impairments following galanin administration.
Together with results from previous studies indicating galanin inhibits CREB
phosphorylation (Kinney et al., 2009), these findings could potentially support a role for
galanin in the preservation of a damaged nervous system in response to cellular insults as
may be occurring in AD.
The cognitive effects of galanin overexpression in AD are currently unknown
while many investigators suggest galanin may be exacerbating cognitive deficits by
suppressing cholinergic tone. The current study emphasizes that the spatial learning and
memory impairments following galanin administration are likely distinct from
cholinergic modulation. Previous work indicates perhaps more attention instead should
be paid to galanin’s inhibition of CREB phosphorylation as a potential modulator of
learning and memory (Kinney et al., 2003; Kinney et al., 2009). Further, the data suggest
galanin administration may be beneficial for spatial learning in an animal model of AD
mimicking cholinergic loss as well as in other studies following infusion of Aβ peptide
(Cheng & Yu, 2010). Although more studies are necessary to elucidate any
neuroprotective effects of galanin in vivo, our data argue for a reappraisal of the role of
galanin in learning and memory as well as AD. These findings may also impact the utility
of administering galanin receptor ligands both in AD as well as other neurodegenerative
disorders.
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